Brokerages Set enGene Holdings Inc. (NASDAQ:ENGN) PT at $33.67

enGene Holdings Inc. (NASDAQ:ENGN) has been given an average rating of “Buy” by the seven research firms that are currently covering the stock, Marketbeat Ratings reports. Seven research analysts have rated the stock with a buy rating. The average twelve-month target price among analysts that have issued ratings on the stock in the last year is $33.67.

A number of equities research analysts recently weighed in on ENGN shares. Oppenheimer restated an “outperform” rating and issued a $30.00 price target on shares of enGene in a research note on Tuesday, September 24th. Morgan Stanley reissued an “overweight” rating and issued a $40.00 price objective on shares of enGene in a research report on Wednesday, September 11th.

Insiders Place Their Bets

In other enGene news, major shareholder Growth Opportunities F. Forbion bought 41,639 shares of enGene stock in a transaction dated Friday, September 27th. The stock was bought at an average price of $5.97 per share, with a total value of $248,584.83. Following the completion of the transaction, the insider now owns 2,059,459 shares in the company, valued at $12,294,970.23. The trade was a 0.00 % increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Ronald Harold Wilfred Cooper acquired 10,000 shares of the stock in a transaction on Friday, September 27th. The shares were purchased at an average price of $5.70 per share, for a total transaction of $57,000.00. Following the purchase, the chief executive officer now directly owns 10,000 shares in the company, valued at approximately $57,000. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Growth Opportunities F. Forbion acquired 41,639 shares of the company’s stock in a transaction on Friday, September 27th. The stock was bought at an average cost of $5.97 per share, with a total value of $248,584.83. Following the completion of the acquisition, the insider now directly owns 2,059,459 shares in the company, valued at approximately $12,294,970.23. This represents a 0.00 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought 420,965 shares of company stock worth $2,651,103 in the last 90 days. Company insiders own 13.70% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of ENGN. Logos Global Management LP grew its stake in enGene by 50.0% during the second quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock worth $11,316,000 after buying an additional 400,000 shares in the last quarter. SR One Capital Management LP acquired a new stake in shares of enGene during the 2nd quarter worth approximately $4,715,000. Janus Henderson Group PLC bought a new position in enGene in the first quarter valued at approximately $17,095,000. Finally, Altitude Crest Partners Inc. bought a new position in enGene in the first quarter valued at approximately $2,039,000. Institutional investors own 64.16% of the company’s stock.

enGene Stock Down 3.0 %

enGene stock opened at $9.02 on Thursday. enGene has a fifty-two week low of $4.42 and a fifty-two week high of $43.00. The firm has a market capitalization of $398.38 million, a PE ratio of -5.24 and a beta of -0.69. The company’s 50-day moving average is $6.71 and its 200-day moving average is $9.73. The company has a debt-to-equity ratio of 0.09, a current ratio of 19.52 and a quick ratio of 19.52.

enGene (NASDAQ:ENGN) last released its quarterly earnings data on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.37) by $0.05. Sell-side analysts anticipate that enGene will post -1.56 earnings per share for the current year.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.